In today’s video interview LSIPR speaks to Dr Ruhong Jiang, president of biotechnology company Applied StemCell, about its work with the CRISPR/Cas9 technology.
In 2014, Applied StemCell, announced that it had entered a licensing agreement with the Broad Institute of MIT and Harvard for use and commercialisation of CRISPR/Cas9 gene editing technology.
He talks to LSIPR about the influential technology.
Ruhong Jiang, Applied StemCell, CRISPR/Cas-9, BIO 2016, Broad Institute
